Author: Liao, Yuqian; Liao, Yulu; Li, Jun; Li, Junyu; Fan, Ying; Xu, Binghe
Title: Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy Cord-id: 942634t2 Document date: 2018_9_21
ID: 942634t2
Snippet: PURPOSE: Triple-negative breast cancer (TNBC) is more than a single disease. Identifying biomarkers to further subdivide TNBC patients with distinct outcome is of great importance. It has been reported that single-nucleotide polymorphisms (SNPs) in Aurora kinase A (AURKA) or Aurora kinase B (AURKB) are associated with the risk and survival of several cancers. But till now, there is no research about these polymorphisms in TNBC patients. MATERIALS AND METHODS: In this study, we investigated the a
Document: PURPOSE: Triple-negative breast cancer (TNBC) is more than a single disease. Identifying biomarkers to further subdivide TNBC patients with distinct outcome is of great importance. It has been reported that single-nucleotide polymorphisms (SNPs) in Aurora kinase A (AURKA) or Aurora kinase B (AURKB) are associated with the risk and survival of several cancers. But till now, there is no research about these polymorphisms in TNBC patients. MATERIALS AND METHODS: In this study, we investigated the association between polymorphisms in AURKA or AURKB gene and prognosis of TNBC patients treated with taxane-based adjuvant chemotherapy. A total of 273 TNBC patients were enrolled. Haploview 4.2 software was used to identify Tag SNPs. Genotyping was conducted using the MassARRAY MALDI-TOF system. RESULTS: We found that AURKA rs6099128 GG genotype carriers had significantly worse overall survival (OS) than TT+ TG genotype carriers (P = 0.003, HR = 12.499, 95% CI = 2.357–66.298). AURKB rs11651993 TT genotype carriers had better disease-free survival (DFS) than TC + CC genotype carriers (P = 0.018, HR = 1.876, 95% CI = 1.116–3.154). AURKB rs2289590 CC genotype carriers had worse DFS than CA + AA genotype carriers (P = 0.021, HR = 0.536, 95% CI = 0.315–0.912). After subgroup analysis, rs11651993 TC + CC genotype predicted worse DFS in subgroups of age ≤ 50, post-menopausal, grade unknown (UK), tumor size >2 cm, and lymph node negative. Rs2289590 CA + AA genotype could predict favorable DFS in pre-menopausal, grade 3 and lymph node-positive patients. CONCLUSION: We first demonstrated that polymorphisms in AURKA or AURKB gene might predict the OS or DFS of TNBC patients treated with taxane-based adjuvant chemotherapy.
Search related documents:
Co phrase search for related documents- aa genotype and lymph node: 1, 2
- aa genotype and lymph node negative: 1
- aa genotype and lymph node status: 1, 2
- aa genotype and lymph node status tumor size: 1
- adjuvant chemotherapy and locoregional recurrence: 1
- adjuvant chemotherapy and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- adjuvant chemotherapy and lymph node metastasis: 1, 2, 3, 4, 5
- adjuvant chemotherapy and lymph node negative: 1, 2, 3
- adjuvant chemotherapy and lymph node status: 1
- adjuvant chemotherapy and lymph node status tumor size: 1
- adjuvant setting and lymph node: 1, 2
- locoregional recurrence and lymph node: 1, 2, 3, 4
- locoregional recurrence and lymph node status: 1
- locoregional recurrence and lymph node status tumor size: 1
- low expression and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- low expression and lymph node metastasis: 1, 2, 3, 4, 5, 6
- low expression and lymph node negative: 1
- low expression and lymph node status: 1, 2
Co phrase search for related documents, hyperlinks ordered by date